Horiike A, Wakui H, Sugawara S, Minegishi Y, Tasaka S, Kusumoto S, Sakatani T, Suzuki H, Hosomi Y, Tambo Y, Shimokawa T, Ishida H, Miyauchi E, Naoki K, Fukuhara T, Mura E, Tsurui T, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Manabe R, Shimokawa M, Ohkuma R, Ariizumi H, Kubota Y, Hamada K, Takenoshita S, Ryu K, Sambe T, Inoue E, Wada S, Yoshimura K, Sagara H, Kobayashi S, Tsunoda T. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with =50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clin Cancer Res. 2026 Oct 15; 32(20):4571-4579.

Locatelli F, Karakukcu M, Huynh V, González-Martínez B, Lins MM, Lu MY, Sulis ML, Pauly M, Morris C, Braunlin M, Talpes M, Gore L. Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia. Blood Adv. 2026 Oct 13; 10(19):6567-6577.

Wang ES, Erba H, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano ND, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Oct 01; 148(14):1775-1788.

Evageliou NF, Renfro LA, Vallance KL, Varela CR, Benedetti DJ, Cost NG, Ehrlich PF, Kalapurakal JA, Khanna G, Aldrink JH, Glick RD, Ortiz MV, Parsons LN, Paulino AC, Artunduaga M, Smith EA, Dix DB, Fernandez CV, Dome JS, Geller JI, Mullen EA. Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies. Cancer. 2026 Oct 01; 132(19):e70610.

Tasaki Y, Sato K, Hamamoto S, Sugiyama Y, Ikoma H, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Tomita M, Mimura Y, Nagai T, Unno R, Etani T, Naiki T, Yasui T, Furukawa-Hibi Y. Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. Cancer Med. 2026 Oct; 15(10):e72410.

Bentebibel SE, McGrail DJ, Kochat V, Arslan E, Abdel-Wahab R, Pazdrak B, Murthy R, Tahon NHM, Cho SN, Duose DY, Wani KM, Liu J, Haymaker C, Gomez JA, Sonnemann H, Katailiha AS, Nassif-Rausseo B, Rahim M, Li I, Mayer AT, Yang X, Hsu FJ, Zhang J, Johnson DH, Amaria RN, Glitza Oliva IC, Patel SP, Hwu P, Elsayes KM, Tawbi HA, Burks JK, Bernatchez C, Davies MA, Rai K, Lizée G, Ekmekcioglu S, Diab A. Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study. Cancer Discov. 2026 Sep 01; 16(9):1780-1800.

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.

Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI. A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. Cancer Res Commun. 2026 Sep 01; 6(9):2206-2219.

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep; 27(9):1094-1109.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Altahan A, Andreadis B, Bartlett NL, Budde LE, Caimi PF, DeVos S, Dholaria B, Fayad LE, Gaballa S, Habermann TM, Hernandez-Ilizaliturri F, Hu B, Kamdar M, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Pophali P, Rabinovitch R, Ramakrishnan P, Reid E, Riedell P, Roberts KB, Saha A, Saito NG, Sawalha Y, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Sep; 24(9).